Sucampo Pharmaceuticals Stock Buy Rating target price $9.00 : Sucampo Pharmaceuticals (NASDAQ: SCMP)‘s stock had its “buy” rating restated by equities researchers at Cantor Fitzgerald in a report issued on Thursday, AnalystRatings.Net reports. They currently have a $9.00 target price on the stock.
Sucampo Pharmaceuticals (NASDAQ: SCMP) opened at 6.88 on Thursday. Sucampo Pharmaceuticals has a 1-year low of $3.78 and a 1-year high of $8.50. The stock’s 50-day moving average is currently $5.8. The company has a market cap of $285.6 million and a price-to-earnings ratio of 59.31.
Sucampo Pharmaceuticals (NASDAQ: SCMP) last issued its quarterly earnings data on Wednesday, March 13th. The company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.20. The company had revenue of $34.90 million for the quarter, compared to the consensus estimate of $32.21 million. Analysts expect that Sucampo Pharmaceuticals will post $0.23 EPS for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at Maxim Group reiterated a “buy” rating on shares of Sucampo Pharmaceuticals in a research note to investors on Thursday. They now have a $10.00 price target on the stock. Separately, analysts at TheStreet upgraded shares of Sucampo Pharmaceuticals from a “sell” rating to a “buy” rating in a research note to investors on Thursday. Finally, analysts at Zacks downgraded shares of Sucampo Pharmaceuticals to a “neutral” rating in a research note to investors on Friday, April 5th. They now have a $7.10 price target on the stock.
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. The Company develops and commercializes drugs based on prostones.